文献速递白血病

抑制DYRK1A导致MYC和ERK激活使KMT2A重排急性淋巴细胞白血病细胞对BCL2抑制敏感

DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition.
PubMed 文献 · Leukemia · 2025-03-27

全激酶组CRISPR筛选发现DYRK1A是KMT2A重排B-急性淋巴细胞白血病的潜在治疗靶点。DYRK1A受KMT2A融合蛋白调控,通过调节MYC表达和ERK磷酸化影响细胞增殖。药物抑制DYRK1A在体外和患者来源异种移植小鼠模型中均降低白血病增殖,并诱导BIM表达、降低BCL-XL表达,使细胞对BCL2抑制敏感;双抑制协同降低细胞存活和小鼠白血病负荷。

要点

  • 全激酶组CRISPR筛选确定DYRK1A为KMT2A重排B-ALL的潜在治疗靶点。
  • 药物抑制DYRK1A在体外和患者来源异种移植小鼠中降低白血病增殖。
  • DYRK1A抑制诱导BIM、降低BCL-XL,使KMT2A重排ALL对BCL2抑制敏感。

核心结论

  • 数据确立DYRK1A为KMT2A重排ALL的新型治疗靶点,并证明双重抑制DYRK1A和BCL2是该高危ALL亚型的有效转化治疗策略。

研究设计与样本

  • 采用无偏全激酶组CRISPR筛选,并在体外细胞实验和药物处理的患者来源异种移植小鼠模型中进行验证。

主要发现

  • DYRK1A受KMT2A融合蛋白调控,通过调节MYC表达和ERK磷酸化影响细胞增殖。
  • 药物抑制DYRK1A在体外显著降低人KMT2A重排ALL细胞增殖,在药物处理的患者来源异种移植小鼠模型中有效降低白血病增殖。
  • DYRK1A抑制诱导促凋亡因子BIM表达并降低BCL-XL表达,使KMT2A重排ALL细胞对BCL2抑制敏感。
  • 双重抑制DYRK1A和BCL2在体外协同降低KMT2A重排ALL细胞存活,并减少小鼠白血病负荷。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Unbiased kinome-wide CRISPR screening identified DYRK1A as a potential therapeutic target in KMT2A-rearranged (KMT2A-R) B-acute lymphoblastic leukemia (ALL). Mechanistically, we demonstrate that DYRK1A is regulated by the KMT2A fusion protein and affects cell proliferation by regulating MYC expression and ERK phosphorylation. We further observed that pharmacologic DYRK1A inhibition markedly reduced human KMT2A-R ALL cell proliferation in vitro and potently decreased leukemia proliferation in vivo in drug-treated patient-derived xenograft mouse models. DYRK1A inhibition induced expression of the proapoptotic factor BIM and reduced the expression of BCL-XL, consequently sensitizing KMT2A-R ALL cells to BCL2 inhibition. Dual inhibition of DYRK1A and BCL2 synergistically decreased KMT2A-R ALL cell survival in vitro and reduced leukemic burden in mice. Taken together, our data establishes DYRK1A as a novel therapeutic target in KMT2A-R ALL and credential dual inhibition of DYRK1A and BCL2 as an effective translational therapeutic strategy for this high-risk ALL subtype.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ayyadevara VSSA, Wertheim G, Gaur S, et al. DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition. Leukemia. 2025. PMID: 40148558. doi:10.1038/s41375-025-02575-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。